Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been diagnosed by an endocrinologist and confirmed by clinical features and biochemical tests

Find the Shared Care Guideline for the NEW initiation of Topical (Testogel®, Testavan®) and injectable Testosterone (Nebido®) for adult male patients with hypogonadism under section 6.4

MHRA - Topical testosterone (Testogel): risk of harm to children following accidental exposure

Initiation must only be made by an endocrinologist on diagnosis of male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Drug must be initiated and titrated to stable dosage by endocrinologist before GPs take over prescribing responsibility. Once medical condition and drug dosage is stable, there is no specific requirement for ongoing monitoring to be completed by GPs

All ongoing monitoring, including Testosterone levels, prostate exam, FBC, Lipid profile, LFT's will be completed by endocrinology at intervals defined by the consultant.

Any dosage adjustments required will be completed by the endocrinologist and a letter will be sent to the GP informing them of this change

Dosages will be prescribed in accordance with the Summary of Product Characteristics

Doncaster & Bassetlaw Area Prescribing Committee
DBHFT Endocrinology
November 2010

Transgender woman medication

Refer to Transgender Women Prescribing Guidance in section 6.4

Transgender man medication

Refer to Transgender Men Prescribing Guidance in section 6.4

Transgender woman medication

Refer to Transgender Women Prescribing Guidance in section 6.4

Transgender man medication

Refer to Transgender Men Prescribing Guidance in section 6.4

Transgender man medication

Refer to Transgender Men Prescribing Guidance in section 6.4

Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been diagnosed by an endocrinologist and confirmed by clinical features and biochemical tests

Initiation must only be made by an endocrinologist on diagnosis of male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Drug must be initiated and titrated to stable dosage by endocrinologist before GPs take over prescribing responsibility. Once medical condition and drug dosage is stable, there is no specific requirement for ongoing monitoring to be completed by GPs

All ongoing monitoring, including Testosterone levels, Prostate exam, FBC, Lipid profile and LFT's will be completed by endocrinology at intervals defined by the consultant.

Any dosage adjustments required will be completed by the endocrinologist and a letter will be sent to the GP informing them of this change

Dosages will be prescribed in accordance with the Summary of Product Characteristics

Doncaster & Bassetlaw Area Prescribing Committee
DBHFT Endocrinology
November 2010

Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been diagnosed by an endocrinologist and confirmed by clinical features and biochemical tests

Testosterone enantate, Testosterone undecanoate 

Initiation must only be made by an endocrinologist on diagnosis of male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Drug must be initiated and titrated to stable dosage by endocrinologist before GPs take over prescribing responsibility. Once medical condition and drug dosage is stable, there is no specific requirement for ongoing monitoring to be completed by GPs

All ongoing monitoring, including Testosterone levels, FBC, prostate exam, Lipid profile, LFT's will be completed by endocrinology at intervals defined by the consultant.

Any dosage adjustments required will be completed by the endocrinologist and a letter will be sent to the GP informing them of this change

Dosages will be prescribed in accordance with the Summary of Product Characteristics

Doncaster & Bassetlaw Area Prescribing Committee
DBHFT Endocrinology
November 2010